newsfilter
← Latest News
ACCESS Newswire·

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

ZÜRICH, SWITZERLAND / ACCESSWIRE / December 3, 2024 / NLS Pharmaceutics Ltd. , a biopharmaceutical company, is pleased to share preclinical data demonstrating the potential of its